VIPRD
Virtual Institute on Poverty Related Diseases

BIKTARVY

BIKTARVY¬ģ combines the DESCOVY¬ģ (FTC/TAF)* backbone with bictegravir, a novel, and unboosted INSTI‚ÄĒfor a powerful STR with a high barrier to resistance1,2

No treatment-emergent resistance was associated with BIKTARVY in treatment-na√Įve clinical trials through Week 96 and in virologically suppressed clinical trials through Week 48‚Ć

Name: BIKTARVY